With over 20 years of experience in the biotechnology/ pharmaceutical industry. Dr. Shames brings expertise in developing and executing innovative high-value clinical program opportunities, building and leading multidisciplinary development organizations, managing successful global regulatory interactions, and providing clinical leadership in IPO and equity financings. He adds strong scientific and medical expertise to Inmagene’s Immunology focus.
Dr. Shames has previously held leadership positions at Protagonist Therapeutics (Chief Medical Officer), Aldea Pharmaceuticals (Chief Medical Officer/ SVP), Merck & Co. (Distinguished Scientist, Clinical Research/ Early Immunology Biologics Lead) and Facet Biotech/ PDL Biopharma (Immunology Therapeutic Area Head) directing biologics, small molecule and peptide drug development programs across multiple disease indications. He has led development programs for FDA-approved products in chronic psoriasis (Ilumya™), multiple sclerosis (Zinbryta®), and autoimmune diseases (Hadlima™).
Dr. Shames previously held full time faculty positions in Pediatric Allergy/ Clinical Immunology at Stanford University Medical Center and University of California, San Francisco School of Medicine. He completed Pediatrics training at Montefiore Hospital-Albert Einstein College of Medicine (New York) and post-doctoral training in Allergy and Clinical Immunology at U.C.S.F., earning Board Certification in Pediatrics and Allergy/ Clinical Immunology. Dr. Shames received his M.D. from the University of California (Davis) School of Medicine and B.S. in Biological Sciences from Stanford University.